Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer

by Bai, H., Chen, H., Cseh, A., Duan, J., Huang, D.C.-L, Tian, Y., Wang, J., Wang, X., Wang, Y., Wu, Y.-L, Xue, Z., Zhao, J.
Published 2022